Last reviewed · How we verify
Disci/Rhus toxicodendron comp.®
A homeopathic combination remedy containing Rhus toxicodendron (poison ivy) and other botanical components designed to modulate immune tolerance and reduce inflammatory responses.
A homeopathic combination remedy containing Rhus toxicodendron (poison ivy) and other botanical components designed to modulate immune tolerance and reduce inflammatory responses. Used for Contact dermatitis and allergic skin reactions, Rheumatoid arthritis and joint inflammation.
At a glance
| Generic name | Disci/Rhus toxicodendron comp.® |
|---|---|
| Sponsor | Charite University, Berlin, Germany |
| Drug class | Homeopathic combination remedy |
| Modality | Small molecule |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 3 |
Mechanism of action
Disci/Rhus toxicodendron comp. is a classical homeopathic preparation that combines Rhus toxicodendron with other ingredients. In homeopathic theory, it is intended to work through immune tolerance mechanisms, potentially desensitizing the immune system to allergens or inflammatory triggers. The mechanism is based on homeopathic principles rather than conventional pharmacology.
Approved indications
- Contact dermatitis and allergic skin reactions
- Rheumatoid arthritis and joint inflammation
Common side effects
- Homeopathic aggravation (temporary symptom exacerbation)
- Allergic reaction to Rhus toxicodendron component
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Disci/Rhus toxicodendron comp.® CI brief — competitive landscape report
- Disci/Rhus toxicodendron comp.® updates RSS · CI watch RSS
- Charite University, Berlin, Germany portfolio CI